CNB Bank Lowers Stake in Pfizer Inc. (NYSE:PFE)

CNB Bank reduced its holdings in shares of Pfizer Inc. (NYSE:PFEFree Report) by 1.6% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 67,879 shares of the biopharmaceutical company’s stock after selling 1,079 shares during the period. Pfizer accounts for about 1.0% of CNB Bank’s investment portfolio, making the stock its 21st largest holding. CNB Bank’s holdings in Pfizer were worth $1,954,000 as of its most recent SEC filing.

A number of other large investors also recently bought and sold shares of the business. Worth Asset Management LLC purchased a new position in Pfizer in the first quarter worth about $29,000. Briaud Financial Planning Inc purchased a new position in Pfizer in the third quarter worth about $30,000. GoalVest Advisory LLC raised its holdings in Pfizer by 304.9% in the fourth quarter. GoalVest Advisory LLC now owns 1,077 shares of the biopharmaceutical company’s stock worth $31,000 after buying an additional 811 shares during the last quarter. Mizuho Securities Co. Ltd. purchased a new position in Pfizer in the third quarter worth about $34,000. Finally, VisionPoint Advisory Group LLC raised its holdings in Pfizer by 52,350.0% in the third quarter. VisionPoint Advisory Group LLC now owns 1,049 shares of the biopharmaceutical company’s stock worth $35,000 after buying an additional 1,047 shares during the last quarter. 68.36% of the stock is owned by hedge funds and other institutional investors.

Pfizer Stock Performance

Shares of NYSE PFE opened at $26.00 on Friday. The firm has a 50 day moving average of $27.11 and a 200 day moving average of $28.65. The company has a current ratio of 0.91, a quick ratio of 0.69 and a debt-to-equity ratio of 0.69. The firm has a market capitalization of $147.23 billion, a price-to-earnings ratio of 72.22, a price-to-earnings-growth ratio of 1.17 and a beta of 0.61. Pfizer Inc. has a 12-month low of $25.23 and a 12-month high of $40.37.

Pfizer (NYSE:PFEGet Free Report) last announced its earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.10 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.19) by $0.29. The company had revenue of $14.25 billion during the quarter, compared to analyst estimates of $14.37 billion. Pfizer had a net margin of 3.62% and a return on equity of 10.88%. The firm’s quarterly revenue was down 41.3% compared to the same quarter last year. During the same period in the previous year, the business posted $1.14 earnings per share. On average, research analysts anticipate that Pfizer Inc. will post 2.24 earnings per share for the current year.

Analysts Set New Price Targets

Several research analysts have issued reports on the stock. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $45.00 target price on shares of Pfizer in a report on Monday, April 15th. Guggenheim assumed coverage on shares of Pfizer in a report on Friday, February 23rd. They issued a “buy” rating and a $36.00 target price for the company. TD Cowen cut shares of Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 target price for the company. in a report on Thursday, January 4th. Finally, Argus lowered shares of Pfizer from a “buy” rating to a “hold” rating in a research note on Friday, March 22nd. Twelve equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. Based on data from MarketBeat.com, Pfizer currently has a consensus rating of “Hold” and a consensus price target of $36.88.

Read Our Latest Analysis on Pfizer

Pfizer Company Profile

(Free Report)

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

See Also

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFEFree Report).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.